2008
The era of personalized medicine: back to basics
Hutchinson L, DeVita V. The era of personalized medicine: back to basics. Nature Reviews Clinical Oncology 2008, 5: 623-623. PMID: 18957968, DOI: 10.1038/ncponc1253.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabClinical Trials as TopicColorectal NeoplasmsDrug Delivery SystemsDrug Resistance, NeoplasmGene TargetingGenes, erbB-1HumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung NeoplasmsPanitumumabPatient-Centered CarePiperazinesPyrimidinesTreatment Outcome
2005
Shifting paradigms in lung cancer
DeVita V. Shifting paradigms in lung cancer. Nature Reviews Clinical Oncology 2005, 2: 535-535. PMID: 16270076, DOI: 10.1038/ncponc0345.Peer-Reviewed Original Research
1986
The effect of combined modality therapy on local control and survival
DeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsBreast NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyFemaleHumansKidney NeoplasmsLung NeoplasmsLymphomaNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasmsPrognosisSarcomaSoft Tissue NeoplasmsWilms TumorConceptsLocal controlSystemic treatmentTumor typesPresence of micrometastasesEffective systemic therapyTumor cell numberLocal control measuresModality therapySystemic therapyCommon cancerMetastatic cancerLESS surgeryRadiation therapyTherapeutic programMetastatic processMicrometastasesTherapySurvivalSystemic componentCell numberTumorsMetastasis genesCancerSubstantial numberInverse relationshipLung cancer rates are alarming and are NCI's greatest challenge.
DeVita V. Lung cancer rates are alarming and are NCI's greatest challenge. Public Health Reports 1986, 101: 5. PMID: 3080790, PMCID: PMC1477644.Peer-Reviewed Original Research
1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancerEvidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene M, Young R, Merrill J, DeVita V. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research 1983, 43: 1891-8. PMID: 6572558.Peer-Reviewed Original ResearchConceptsRisk of acute nonlymphocytic leukemiaNon-Hodgkin's lymphomaAcute nonlymphocytic leukemiaCases of acute nonlymphocytic leukemiaNonlymphocytic leukemiaTherapy of non-Hodgkin's lymphomaNon-Hodgkin lymphoma cohortNon-Hodgkin's lymphoma patientsSingle-modality therapyModel of leukemogenesisCase-control studyCumulative radiation dosePatients per yearOptimum patient managementHemibody radiationLeukemogenic therapyNational Cancer InstituteChemotherapy durationHistological subtypesChemotherapy doseTreatment regimensBone marrowTotal bodyPatient managementTherapy
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
1975
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRisk
1974
Cyclical Combination Chemotherapy for Advanced Breast Carcinoma
Canellos G, Devita V, Gold G, Chabner B, Schein P, Young R. Cyclical Combination Chemotherapy for Advanced Breast Carcinoma. The BMJ 1974, 1: 218. PMID: 4818162, PMCID: PMC1633086, DOI: 10.1136/bmj.1.5901.218.Peer-Reviewed Original ResearchConceptsMedian survivalMetastatic lesionsAdvanced metastatic breast cancerCyclical combination chemotherapyOverall median durationAdvanced breast carcinomaBone marrow involvementMetastatic breast cancerMetastasis-free intervalSoft tissueExtensive radiotherapyPrevious chemotherapyComplete remissionHaematological toxicityHormonal therapyLiver dysfunctionMarrow involvementMedian durationCombination chemotherapyEndocrine ablationBreast carcinomaBreast cancerPatientsMonthly cyclesChemotherapy
1972
In vivo tumor cell kinetic studies: use of local thymidine injection followed by fine-needle aspiration.
Muggia F, DeVita V. In vivo tumor cell kinetic studies: use of local thymidine injection followed by fine-needle aspiration. Translational Research 1972, 80: 297-301. PMID: 5044784.Peer-Reviewed Original Research
1970
Combination chemotherapy in the treatment of advanced Hodgkin's disease.
Devita V, Serpick A, Carbone P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Annals Of Internal Medicine 1970, 73: 881-95. PMID: 5525541, DOI: 10.7326/0003-4819-73-6-881.Peer-Reviewed Original Research
1965
PULMONARY MANIFESTATIONS OF PRIMARY HEPATIC CARCINOMA
DeVita V, Trujillo N, Blackman A, Ticktin H. PULMONARY MANIFESTATIONS OF PRIMARY HEPATIC CARCINOMA. The American Journal Of The Medical Sciences 1965, 250: 428-436. PMID: 4284660, DOI: 10.1097/00000441-196510000-00009.Peer-Reviewed Original Research